Abstract: The present invention relates to a method and system for analyzing mechanical signatures of a plurality of cells for metastatic detection. Specifically, a data set characterized by at least one metric (such as Brillouin frequency shift and/or Brillouin linewidth) representing a cell mechanical signature is acquired for the plurality of cells by using a label-free Brillouin spectroscopy. A merit function is calculated based on one or more statistical characteristics of the data set, such as sensitivity and specificity. Then, the plurality of cells can be classified to detect metastatic cells based on mechanical signatures provided by the data set and an optimal metric value delivering maximum to the merit function.

Abstract: Systems and methods are disclosed to objectively identify sub-second behavioral modules in the three-dimensional (3D) video data that represents the motion of a subject. Defining behavioral modules based upon structure in the 3D video data itself—rather than using a priori definitions for what should constitute a measurable unit of action—identifies a previously-unexplored sub-second regularity that defines a timescale upon which behavior is organized, yields important information about the components and structure of behavior, offers insight into the nature of behavioral change in the subject, and enables objective discovery of subtle alterations in patterned action. The systems and methods of the invention can be applied to drug or gene therapy classification, drug or gene therapy screening, disease study including early detection of the onset of a disease, toxicology research, side-effect study, learning and memory process study, anxiety study, and analysis in consumer behavior.

Abstract: Methods and compositions for clonally inhibiting or clonally stimulating T-cells are provided.

Abstract: The present disclosure relates to a biosensor capable of measuring the total concentration of one or a plurality of ammonia or ammonium ions with the use of indophenol reagents in the presence of an ionomer. In some embodiments, the biosensor comprises a perflurinated membrane that comprises an ionomer in contact with an alkali buffer in a vessel configured to receive a sample, such as whole blood. The disclosure also relates to a method of detecting or quantifying the ammonia or ammonium ion concentration in whole blood in a point of care bio sensor without reliance on gas chromatography or any measurement that takes more than about twenty minutes.

Abstract: Disclosed herein are organ chips that can be individually used or integrated together to form different microphysiological systems, e.g., for use in cell culturing, drug screening, toxicity assays, personalized therapeutic treatment, scaffolding in tissue repair and/or replacement, and/or pharmacokinetic or pharmacodynamics studies.

Abstract: The present disclosure provides liposomes comprising a membrane and an intraliposomal aqueous water phase, the membrane comprising at least one liposome forming lipid and the intraliposomal aqueous water phase comprises a salt of a bisphosphonate together with an amphipathic weak base agent (PLAD). An example of a liposome is one comprising co encapsulated in the intraliposomal aqueous water phase N-containing bisphosphonate, such as alendronate, and an anthracycline such as doxorubicin which was shown to increase survival as compared to Doxil or to administrations of liposomal alendronate (PLA) and Doxil (separate liposomes). Such liposomes may carry a targeting moiety exposed at the liposome's outer surface, for example, conjugate of folic acid as a targeting moiety to folate receptor (FT-PLAD). Also provided by the present disclosure is a method of preparing the liposomes and methods of use of the liposomes, at times, in combination with additional active ingredients, such as ?? T-cells.

Abstract: A contact-type endoscope surface enhanced Raman scattering (SERS) probe includes a gradient-index (GRIN) lens, a transparent substrate adhered to the GRIN lens, and a rough metallic layer adhered to an opposite side of the transparent substrate from the GRIN lens. The GRIN lens focuses light from a Raman spectrometer onto the rough metallic layer, and the rough metallic layer is positioned at the distal end of the contact-type endoscope SERS probe.

Abstract: The invention includes, in part, methods and compounds for treating diseases and conditions characterized by elevated threonyl-tRNA synthetase (TARS) activity, which include, but are not limited to diseases and conditions in which angiogenesis is elevated as compared to normal. In some embodiments of the invention, a level of a TARS molecule is determined and compared to a control level of TARS to assess a treatment for a disease or condition characterized by elevated TARS activity.

Abstract: Described herein are fluid-flow control devices for transferring a fluid from a place to another and/or controlling a fluid flow. In some embodiments, fluid-flow control devices described herein can be used as pumping devices to transfer a fluid by peristaltic motion and/or as valve devices to control fluid flow for various applications, e.g., in a microfluidic platform.

Abstract: In a method for interactive marking by a mobile robot on a vertical surface, a mobile robot that includes a sensor and an actuated marker is displaced across a vertical surface. Features on, in or behind the vertical surface are detected with the sensor. Displacement of the mobile robot and actuation of the actuated marker is controlled in response to the detection of these features.

Abstract: Methods and compositions are provided for inhibiting or treating metastasis based on discoveries regarding Kif19 and Cep192. Methods and compositions are provided for enhancing wound healing, treating fibrosis, reducing scarring and treating nerve pain.

Abstract: Embodiments of the present invention include methods for increasing off-chip bandwidth. The method includes designing a circuit of switchable pins, replacing a portion of allocated pins of a processor with switchable pins, connecting the processor to a memory interface configured to switch the switchable pins between a power mode and a signal mode, providing a metric configured to identify which of the power mode and the signal mode is most beneficial during 1 millisecond intervals, and switching the switchable pins to signal mode during intervals where the signal mode provides more benefit than the power mode.

Abstract: Provided a method and system for computing a bandwidth requirement for a cellular operator from shared spectrum in a cellular network, the shared spectrum comprising at least one shared spectrum class which is accessible by multiple entities, the method comprising: computing an average user throughput in the cellular network; comparing the average user throughput to a target minimum average user throughput, taking into account an average percentage of users within coverage and a coverage probability threshold; and based on the comparison, computing an additional bandwidth requirement from the at least one shared spectrum class.

Abstract: Disclosed are 13C and 15N derivatization reagents and their use for gas chromatography-mass spectroscopy and liquid chromatography/mass spectroscopy chemical identification and quantification.

Abstract: Methods and agents are provided for inhibiting interleukin 1 receptor accessory protein (IL1RAP) protein-protein interaction to treat a broad spectrum of diseases and conditions.

Abstract: Embodiments of the present disclosure pertain to methods of inhibiting cancer cells by exposing the cancer cells to a purinergic receptor antagonist that targets one or more purinergic receptors of the cancer cells. The targeted purinergic receptors can include P2 purinergic receptors, such as P2X purinergic receptor subtypes (e.g., P2X3 or P2X5) and P2Y purinergic receptor subtypes (e.g., P2Y2). In some embodiments, the inhibited cancer cells are associated with hepatocellular carcinoma. In additional embodiments, the present disclosure pertains to methods of treating hepatocellular carcinoma in a subject by administering a purinergic receptor antagonist to the subject such that the antagonist targets one or more purinergic receptors of hepatocellular carcinoma cells in the subject. In some embodiments, the subject is a human being suffering from hepatocellular carcinoma.

Abstract: A system and method for cognitive risk mitigation are presented. Embodiments comprise journey prediction, parsing of data sources, risk assessment and mitigation, and natural-language user interaction by a cognitive processor. Data is gathered from a plurality of data sources and analyzed in the context of one or more of the user's intention(s). A dialogue with the user, in natural language, aims to provide and select one or more suggestions relating to the one or more user intention(s) such that the risk(s) relating to the one or more user's intention(s) is reduced. During the dialogue, cognitive reasoning may be performed, wherein the cognitive reasoning includes the ability to justify each suggestion and the ability to infer information from the interaction such as, for example, data obtained in a dialogue may inform subsequent inferences. The embodiments may use speech synthesis and speech recognition in an interactive spoken dialogue.

Abstract: Disclosed are tumor necrosis factor receptor 1B (TNFR-1B) signaling targets and TNFR-1B mutants and their uses for treatment of diseases and disorders.

Abstract: The invention relates to the use of an Engrailed protein as a medicament for increasing dopamine synthesis by dopaminergic neurons, in particular in the management of conditions associated with a decrease of dopamine levels without loss of dopaminergic neurons.

Abstract: The embodiments disclosed herein utilized RNA targeting effectors to provide a robust CRISPR-based diagnostic with attomolar sensitivity. Embodiments disclosed herein can detect broth DNA and RNA with comparable levels of sensitivity and can differentiate targets from non-targets based on single base pair differences. Moreover, the embodiments disclosed herein can be prepared in freeze-dried format for convenient distribution and point-of-care (POC) applications. Such embodiments are useful in multiple scenarios in human health including, for example, viral detection, bacterial strain typing, sensitive genotyping, and detection of disease-associated cell free DNA.